Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

ABSTRACT:

Background

The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.

Methods

EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m², or 45 to less than 90 mL/min per 1·73 m² with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or hi

SUBMITTER: EMPA-KIDNEY Collaborative Group 

PROVIDER: S-EPMC7618536 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature